“This clinical trial will evaluate the ability of AVID200 to achieve the disease-modifying outcomes of reversing bone marrow fibrosis and restoring normal hematopoiesis. Preclinical data demonstrate that selective neutralization of TGF-beta 1 & 3 by AVID200 results in both of these critical outcomes. We believe that AVID200 has the potential to become the first disease-modifying treatment for MF,” commented Dr. Ronald Hoffman, founder of the MPN-RC and Director of the Myeloproliferative Disorders Research Program at the Icahn School of Medicine at Mount Sinai.
Written by
Paul123456
To view profiles and participate in discussions please or .
Thank you Paul for sharing this information..... always encouraging to hear of potential new treatments entering clinical trials. Please keep posting !
One thing that puzzles me is why drug treatments for MF seem to be the research focus when MF is such a rare condition even within the MPN group. As we saw at the Oxford forum : only half a dozen people in the MF breakout group.
I’m not complaining, because MF is what I have, but I don’t get the economics of it.
I think there are a number of reasons; although rare, mf affects 30,000 people in the U.S. alone. That is a lot of people. Also many mpn patients with ET and PV do progress to MF. Finally, the fatality rate for patients with mf is much more grim than those with other mpns; that alone is a good reason for the research. By the way, I was in attendance at the MPN conference at the Mayo clinic, and there were a lot of mf patients present. Finally, Leukemia kills about 350,000 a year world wide, and mf develops into a very serious form of leukemia about 20-25% of the time, so again, morbidity is a huge reason for research. MPNS are rare overall, but not as rare as a lot of us think, there has been a lot of mis-diagnosis of the disease historically. Now that awareness is increasing, so are rates.
Thank you for your response: those numbers make sense. As I said, MF is what I have, and ruxolitnib has helped a lot, but it’s a pity that its main side effect is anaemia leading to fatigue.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
tasquinimod in myelofibrosis (MF)
Treatment-free remission as a new goal for patients with PV
Possible ET but triple negative
UPDATE: WARWICK's ASCT Journey...
